Treatment of chronic hepatitis C with recombinant alpha 2b interferon in kidney transplant recipients: preliminary results and side effects.
Rostaing
L
L
Unité de Transplantation d'Organes, CHU Rangueil, Toulouse, France.
Izopet
J
J
Baron
E
E
Duffaut
M
M
Puel
J
J
Durand
D
D
D000328:Adult; D000368:Aged; D001219:Aspartate Aminotransferases / Q000097:blood; D002908:Chronic Disease; D003404:Creatinine / Q000097:blood; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000032:analysis; D006526:Hepatitis C / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000502:physiology; D007958:Leukocyte Count; D008875:Middle Aged; D010976:Platelet Count; D011183:Postoperative Complications / Q000628:therapy / Q000821:virology; D011994:Recombinant Proteins; D013997:Time Factors; D014766:Viremia / Q000628:therapy; D005723:gamma-Glutamyltransferase / Q000097:blood
D006454:Hemoglobins; D007166:Immunosuppressive Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D003404:Creatinine; D005723:gamma-Glutamyltransferase; D001219:Aspartate Aminotransferases